The Working Group on Pharmaceutical Safety is continuing its efforts to ensure proper oversight of compounding pharmacies, focusing its efforts on ensuring strong implementation of the law.
November 18, 2013
WASHINGTON – The Working Group on Pharmaceutical Safety today released the following
statements regarding Senate passage of the Drug Quality and Security Act.
Statement from Governor Tommy Thompson: “We commend the bipartisan leadership in the
House and Senate for their tireless work on this important bill, which provides necessary federal
oversight of pharmaceutical quality while preserving the important role of traditional
compounding. This legislation meets the commonsense expectations of patients, who deserve
the peace of mind that the drugs they are taking are safe.”
Background on Working Group Leadership:
Governor Tommy Thompson serves as a co-leader of the Working Group on Pharmaceutical
Safety. Thompson served as U.S. Secretary of Health and Human Services (HHS) from 2001 to
2005, Governor of Wisconsin from 1987 to 2001, and has solved major healthcare delivery, safety
and regulatory problems at the federal and state levels. He is currently Chairman of
As Congress considered legislation to address the oversight of compounding pharmacies, the Working Group on Pharmaceutical Safety released an independent survey highlighting the large gap between voters' expectations that the medications they receive are FDA-approved and loopholes in federal law that enable some pharmacies to avoid Food and Drug Administration (FDA) regulation. The results of the survey were released one year after contaminated drugs produced at a compounding pharmacy – the New England Compounding Center (NECC) – caused a deadly fungal meningitis outbreak that has claimed 64 deaths nationwide and sickened more than 700 others.
Key Findings Include:
To download the full survey, click here.
To view the press release, click here.
The Working Group on Pharmaceutical Safety was created to address serious gaps in current policy that have led to a dangerous increase in the volume of mass-manufactured pharmaceutical products in the United States created under the guise of pharmacy compounding.
In consultation with patient advocates, public health officials, medical professionals and pharmaceutical companies, the Group is committed to finding workable policy solutions to reduce patient exposure to non-medically necessary compounded drugs. These products do not meet federal safety, efficacy and quality standards, and may be unsafe or ineffective.
The Group believes that the preventable cases of patient harm due to medications manufactured by compounding pharmacies are an unnecessary risk to the public health, and should be urgently addressed by policymakers. Clarifying the authority between federal oversight of pharmaceutical manufacturing and state oversight of pharmacists will help reduce current risks to public safety and improve the overall safety and security of the nation’s drug supply.
Learn more about current loopholes that threaten the safety of the U.S. drug supply.
More than 17,000 vials of drugs were shipped to 23 states in Fall 2012. The supposedly sterile drug set off a disaster, ultimately killing 64 people and affecting over 750 other patients due to a fungus in the medicine.